353 related articles for article (PubMed ID: 18927459)
21. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
Zhang Z; Zhang L; Yepes M; Jiang Q; Li Q; Arniego P; Coleman TA; Lawrence DA; Chopp M
Circulation; 2002 Aug; 106(6):740-5. PubMed ID: 12163437
[TBL] [Abstract][Full Text] [Related]
22. Bryostatin extends tPA time window to 6 h following middle cerebral artery occlusion in aged female rats.
Tan Z; Lucke-Wold BP; Logsdon AF; Turner RC; Tan C; Li X; Hongpaison J; Alkon DL; Simpkins JW; Rosen CL; Huber JD
Eur J Pharmacol; 2015 Oct; 764():404-412. PubMed ID: 26189021
[TBL] [Abstract][Full Text] [Related]
23. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis.
Kelly MA; Shuaib A; Todd KG
Exp Neurol; 2006 Jul; 200(1):38-49. PubMed ID: 16624294
[TBL] [Abstract][Full Text] [Related]
24. Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.
Zhang L; Chopp M; Jia L; Cui Y; Lu M; Zhang ZG
J Cereb Blood Flow Metab; 2009 Nov; 29(11):1816-24. PubMed ID: 19638998
[TBL] [Abstract][Full Text] [Related]
25. IMM-H004 prevents toxicity induced by delayed treatment of tPA in a rat model of focal cerebral ischemia involving PKA-and PI3K-dependent Akt activation.
Zuo W; Chen J; Zhang S; Tang J; Liu H; Zhang D; Chen N
Eur J Neurosci; 2014 Jun; 39(12):2107-18. PubMed ID: 24649933
[TBL] [Abstract][Full Text] [Related]
26. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
Ning M; Furie KL; Koroshetz WJ; Lee H; Barron M; Lederer M; Wang X; Zhu M; Sorensen AG; Lo EH; Kelly PJ
Neurology; 2006 May; 66(10):1550-5. PubMed ID: 16717217
[TBL] [Abstract][Full Text] [Related]
27. Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
Jin R; Xiao AY; Liu S; Wang M; Li G
Stroke; 2018 Jul; 49(7):1708-1718. PubMed ID: 29844028
[TBL] [Abstract][Full Text] [Related]
28. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke.
Machado LS; Kozak A; Ergul A; Hess DC; Borlongan CV; Fagan SC
BMC Neurosci; 2006 Jul; 7():56. PubMed ID: 16846501
[TBL] [Abstract][Full Text] [Related]
29. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.
Wang Y; Zhang Z; Chow N; Davis TP; Griffin JH; Chopp M; Zlokovic BV
Stroke; 2012 Sep; 43(9):2444-9. PubMed ID: 22811462
[TBL] [Abstract][Full Text] [Related]
30. Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
Muhammad S; Planz O; Schwaninger M
Cerebrovasc Dis Extra; 2016; 6(2):50-9. PubMed ID: 27560521
[TBL] [Abstract][Full Text] [Related]
31. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia.
Tsuji K; Aoki T; Tejima E; Arai K; Lee SR; Atochin DN; Huang PL; Wang X; Montaner J; Lo EH
Stroke; 2005 Sep; 36(9):1954-9. PubMed ID: 16051896
[TBL] [Abstract][Full Text] [Related]
32. PI3Kγ (Phosphoinositide 3-Kinase-γ) Inhibition Attenuates Tissue-Type Plasminogen Activator-Induced Brain Hemorrhage and Improves Microvascular Patency After Embolic Stroke.
Jin R; Xiao AY; Li J; Wang M; Li G
Hypertension; 2019 Jan; 73(1):206-216. PubMed ID: 30571560
[TBL] [Abstract][Full Text] [Related]
33. Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator.
Lapchak PA; Zivin JA
Stroke; 2003 Aug; 34(8):2013-8. PubMed ID: 12855833
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke.
Fukuta T; Asai T; Yanagida Y; Namba M; Koide H; Shimizu K; Oku N
FASEB J; 2017 May; 31(5):1879-1890. PubMed ID: 28082354
[TBL] [Abstract][Full Text] [Related]
35. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.
Lapchak PA; Chapman DF; Zivin JA
Stroke; 2000 Dec; 31(12):3034-40. PubMed ID: 11108768
[TBL] [Abstract][Full Text] [Related]
36. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion.
Pfefferkorn T; Rosenberg GA
Stroke; 2003 Aug; 34(8):2025-30. PubMed ID: 12855824
[TBL] [Abstract][Full Text] [Related]
37. Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.
Zhu H; Fan X; Yu Z; Liu J; Murata Y; Lu J; Zhao S; Hajjar KA; Lo EH; Wang X
J Cereb Blood Flow Metab; 2010 Jun; 30(6):1137-46. PubMed ID: 20068577
[TBL] [Abstract][Full Text] [Related]
38. Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential.
Machado LS; Sazonova IY; Kozak A; Wiley DC; El-Remessy AB; Ergul A; Hess DC; Waller JL; Fagan SC
Stroke; 2009 Sep; 40(9):3028-33. PubMed ID: 19628804
[TBL] [Abstract][Full Text] [Related]
39. Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator.
Lapchak PA; Araujo DM; Song D; Wei J; Purdy R; Zivin JA
Stroke; 2002 Jun; 33(6):1665-70. PubMed ID: 12053009
[TBL] [Abstract][Full Text] [Related]
40. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke.
Lapergue B; Dang BQ; Desilles JP; Ortiz-Munoz G; Delbosc S; Loyau S; Louedec L; Couraud PO; Mazighi M; Michel JB; Meilhac O; Amarenco P
Stroke; 2013 Mar; 44(3):699-707. PubMed ID: 23422087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
